Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 28;12(11):955-974.
doi: 10.14218/JCTH.2024.00311. Epub 2024 Nov 4.

Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024)

Jian-Gao Fan  1 , Xiao-Yuan Xu  2 , Rui-Xu Yang  1 , Yue-Min Nan  3 , Lai Wei  4 , Ji-Dong Jia  5 , Hui Zhuang  6 , Jun-Ping Shi  7 , Xiao-Ying Li  8 , Chao Sun  1 , Jie Li  9 , Vincent Wai-Sun Wong  10 , Zhong-Ping Duan  11 ; Chinese Society of Hepatology, Chinese Medical Association
Affiliations

Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024)

Jian-Gao Fan et al. J Clin Transl Hepatol. .

Abstract

With the rising epidemic of obesity, metabolic syndrome, and type 2 diabetes mellitus in China, metabolic dysfunction-associated non-alcoholic fatty liver disease has become the most prevalent chronic liver disease. This condition frequently occurs in Chinese patients with alcoholic liver disease and chronic hepatitis B. To address the impending public health crisis of non-alcoholic fatty liver disease and its underlying metabolic issues, the Chinese Society of Hepatology and the Chinese Medical Association convened a panel of clinical experts to revise and update the "Guideline of prevention and treatment of non-alcoholic fatty liver disease (2018, China)". The new edition, titled "Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease (Version 2024)", offers comprehensive recommendations on key clinical issues, including screening and monitoring, diagnosis and evaluation, treatment, and follow-up for metabolic dysfunction-associated fatty liver disease and metabolic dysfunction-associated steatotic liver disease. Metabolic dysfunction-associated fatty liver disease is now the preferred English term and is used interchangeably with metabolic dysfunction-associated steatotic liver disease. Additionally, the guideline emphasizes the importance of multidisciplinary collaboration among hepatologists and other specialists to manage cardiometabolic disorders and liver disease effectively.

Keywords: Cardiovascular disease; Guideline; Management; Metabolic dysfunction-associated fatty liver disease; Metabolic dysfunction-associated steatotic liver disease; Non-alcoholic fatty liver disease; Type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

JGF has been an Associate Editor of Journal of Clinical and Translational Hepatology since 2013. YMN has been an Editorial Board Member of Journal of Clinical and Translational Hepatology since 2022. JDJ and LW have been Executive Associate Editors of Journal of Clinical and Translational Hepatology since 2013. CS has been an Editorial Board Member of Journal of Clinical and Translational Hepatology since 2020. JL has been an Editorial Board Member of Journal of Clinical and Translational Hepatology since 2024. The other authors have no conflict of interests related to this publication.

Figures

Fig. 1
Fig. 1. Etiological diagnosis flowchart of fatty liver disease.
HCV, hepatitis C virus; MetS, metabolic syndrome; MAFLD, metabolic dysfunction-associated fatty liver disease; FLD, fatty liver disease; ALD, alcoholic liver disease; BMI, body mass index; WC, waist circumstance; HbA1c, hemoglobin A1c; HOMA-IR, homeostasis model assessment of insulin resistance; TG, triglycerides; HDL-cholesterol, high-density lipoprotein cholesterol; 1 mmHg = 0.133 kPa.
Fig. 2
Fig. 2. Screening, diagnosis and assessment of metabolic dysfunction-associated fatty liver disease.
ALT, alanine aminotransferase; FIB-4, fibrosis-4; LSM, liver stiffness measurement; FAST, Fibro scan-AST; MASH, metabolic dysfunction-associated steatohepatitis; CSPH, clinically significant portal hypertension.
Fig. 3
Fig. 3. The multidisciplinary management for MAFLD.
MAFLD, metabolic dysfunction-associated fatty liver disease; IR, insulin resistance.
See this image and copyright information in PMC

References

    1. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–1835. doi: 10.1097/HEP.0000000000000323. - DOI - PMC - PubMed
    1. National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association, Fatty Liver Expert Committee, Chinese Medical Doctor Association [Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update] Zhonghua Gan Zang Bing Za Zhi. 2018;26(3):195–203. doi: 10.3760/cma.j.issn.1007-3418.2018.03.008. - DOI - PubMed
    1. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) J Hepatol. 2024;81(3):492–542. doi: 10.1016/j.jhep.2024.04.031. - DOI - PubMed
    1. Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851–861. doi: 10.1016/S2468-1253(22)00165-0. - DOI - PubMed
    1. Lou TW, Yang RX, Fan JG. The global burden of fatty liver disease: the major impact of China. Hepatobiliary Surg Nutr. 2024;13(1):119–123. doi: 10.21037/hbsn-23-556. - DOI - PMC - PubMed

LinkOut - more resources